New York, NY -- (SBWIRE) -- 01/10/2014 -- PennyStockChronicle covers the breadth of the markets, from NASDAQ, NYSE, AMEX, ETF, Penny Stocks, Emerging Markets, activities at the Fed and more. PennyStockChronicle brings you the most vibrant coverage of following stocks: BG Medicine, Inc (NASDAQ:BGMD), Xinyuan Real Estate Co., Ltd. (ADR) (NYSE:XIN), Oxygen Biotherapeutics, Inc (NASDAQ:OXBT), Idenix Pharmaceuticals Inc (NASDAQ:IDIX)
BG Medicine, Inc (NASDAQ:BGMD) showed a volume of 1.30 million shares by the end of last trade whereas the average volume of the stock remained 2.90 million shares. The stock opened the session at $1.33 but then moved to $1.35. At that price, the stock showed a positive performance of 1.50%. BG Medicine, Inc. (BG Medicine) is a life sciences company focused on the discovery, development and commercialization of cardiovascular diagnostics to addresses unmet medical needs. The Company focuses on blood-based tests. Its lead product candidate in development is CardioSCORE, which is a multi-analyte biomarker-based blood test for atherothrombotic cardiovascular disease, commonly known as vulnerable plaque. In March 2011,
Will BGMD Continue To Move Higher? Find Out Here
Xinyuan Real Estate Co., Ltd. (ADR) (NYSE:XIN) opened the session at $5.05 and closed the session at $4.90. The stock showed a negative performance of -2.97% in previous trading session. Traded with volume of 1.29 million shares in the prior session and the average volume of the stock remained 397,485.00 shares. Xinyuan Real Estate Co., Ltd. (Xinyuan) is a developer of large-scale residential real estate projects aimed at providing middle-income consumers with a comfortable and convenient community lifestyle. Xinyuan has expanded its network to cover a total population of over 64.7 million people in eight selected cities, consisting Beijing, Hefei, Jinan, Kunshan, Suzhou, Zhengzhou, Xuzhou and Chengdu.
Has XIN Found The Bottom And Ready To Gain Momentum? Find Out Here
Oxygen Biotherapeutics, Inc (NASDAQ:OXBT) opened the session at $5.27 and closed the session at $5.76. The stock showed a positive performance of 9.09% in previous trading session. Traded with volume of 1.29 million shares in the prior session and the average volume of the stock remained 1.36 million shares. The beta of the stock remained 0.46. Oxygen Biotherapeutics, Inc. (Oxygen Biotherapeutics) is engaged in the business of developing biotechnology products with a focus on oxygen delivery to tissue. As of April 30, 2011, the Company is developing Oxycyte, a systemic perfluorcarbon (PFC), product. It has developed a family of perfluorocarbon-based oxygen carriers for use in personal care, topical wound healing, and other topical indications. In addition, Oxygen Biotherapeutics has also have under development Vitavent,
Why Should Investors Buy OXBT After The Recent Gain? Just Go Here and Find Out
Idenix Pharmaceuticals Inc (NASDAQ:IDIX) the stock decreased -0.56% and finished the session at $7.05. Traded with volume of 1.27 million shares in the prior session and the average volume of the stock remained 1.08 million shares. The beta of the stock remained 0.44. Idenix Pharmaceuticals, Inc. (Idenix) is a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases with operations in the United States and France. As of December 31, 2012, the Company's primary research and development focused on the treatment of patients with hepatitis C virus (HCV). In June 2012, the Company completed a three-day proof-of-concept study designed to evaluate 64 treatment-naive HCV genotype 1, 2, 3 or 4-infected patients. In July 2012, the FDA granted Fast Track designation for IDX719.
Will IDIX Get Buyers Even After The Recent Rally? Find Out Here
Penny Stock Chronicle is comprised of a team of vetted penny stock traders who’ve been trading since 2008 & have developed the skills needed to trade for consistent profits.
PLEASE NOTE WELL: The employees of PennyStockChronicle.com are not registered as Investment Advisors in any jurisdiction whatsoever. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. Investing in “penny stocks” is highly speculative.
Verify all claims and do your own due diligence on all securities. PennyStockChronicle.com profiles are not a solicitation or recommendation to buy, sell or hold securities. PennyStockChronicle.com is not offering securities for sale. Neither PennyStockChronicle.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor under any federal or state law and none of the information provided by PennyStockChronicle.com, its owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or investment recommendations. PennyStockChronicle.com does not recommend that the securities profiled should be purchased, sold or held.
Read Full Disclaimer at: http://pennystockchronicle.com/disclaimer
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)